Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Eden vs Kin Meds

Both scored on the same six-factor Match Score. Eden wins this matchup with a 87 to 72 edge.

Higher Match Score

Eden

#7 · Grade B+

People who prioritize a vetted, high-transparency, high-touch provider over the lowest sticker price.

Visit Eden
VS

Kin Meds

#90 · Grade C

People who want compounded and brand-name GLP-1 plus a longevity stack on one platform.

Visit Kin Meds

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
74
72
Speed to Start
90
62
Formulary Match
80
97
Support Level
94
78
Flexibility
90
55
Transparency
92
72

Price, coverage & formulary

DetailEdenKin Meds
Semaglutide$239/mo$149/mo (brand Wegovy)
Tirzepatide$349/mo$149/mo (brand Zepbound)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjectable onlyYes
Match Score87 · B+72 · C
Winner: Eden

Eden edges out Kin Meds, 87 to 72 on the default Match Score. A polished, high-disclosure compounded program with strong nationwide coverage and hands-on support.

Kin Meds is still a fair pick if its strengths line up with yours — best for: People who want compounded and brand-name GLP-1 plus a longevity stack on one platform.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Eden reviewFull Kin Meds review

More head-to-heads

Or browse alternatives to Eden and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.